Biomea Fusion Inc. announced the presentation of results from its COVALENT-111 clinical study at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), held December 3-6, 2025, in Los Angeles. The study evaluated icovamenib, a selective menin inhibitor, in adults with severe insulin-deficient type 2 diabetes. According to the company, icovamenib demonstrated durable glycemic and C-peptide improvements up to 9 months after the last dose, with higher HbA1c reduction associated with greater drug exposure. The treatment was reported to be generally well-tolerated, with no adverse-event related discontinuations or serious adverse events. The full abstract will be published in Metabolism: Experimental and Clinical, and the presentation will be available on Biomea Fusion's Investor Relations page.